Searching for the right type 2 diabetes treatment.
I recently covered both-the European Association for the Study of Diabetes (EASD) and the American Academy of Family Physicians annual meeting. The two meetings posed a contrast in styles for managing obese patients with type 2 diabetes and glycemia that doesn't improve with two or so oral drugs.
Among the endocrinologists at the EASD, opinion tipped toward using insulin when type 2 patients get hard to manage. "We want to encourage physicians to use insulin earlier in type 2 diabetes in general practice, but doctors are afraid of using insulin. They are afraid of hypoglycemia," Dr. John Leahy told me at that meeting. He applauded the results of a study that randomized patients with type 2 diabetes with inadequate glucose control on one or two oral drugs to treatment with insulin or sitagliptin (januvia), a popular oral drug. The findings showed that insulin did significantly better at controlling glucose levels than sitagliptin did, with a decent safety profile.
But the fear about insulin goes beyond hypoglycemia, noted Dr. Frank Domino, when he spoke at the AAFP meeting in Philadelphia.
"I have putting patients on insulin. It will only make the patient more obese and insulin resistant," he said. "If you just treat the [hemoglobin] [A.sub.1c], it doesn't improve outcomes and probably makes some things worse.
Obese patients whose Hb[A.sub.1c] remains above 9% despite treatment with two or three oral drugs need treatment for their chronic disease, obesity, said Dr. Domino. He then gave a qualified shout out to the two newly FDA-approved weight loss drugs, Qsymia, which combines phentermine and topiramate, and lorcaserin, Belviq. While he characterized the Food and Drug Administration as "finally coming to the rescue" by approving this pair of weight-loss drugs, he quickly added: "I'm not encouraging you to use these drugs. I'm encouraging you to think of obesity as a chronic disease that needs all modalities of treatment."
Dr. Domino isn't alone being cautious with weight-loss meds. A recent article in the New England Journal of Medicine written by staffers at the the FDA laid out their rationale for approving the two formulations (2012;367:1577-9). Also in the issue is an interview with drug guru Dr. Jerry Avorn, who spells out his reservations about using these two drugs in practice right now.
Dr. Avorn's concern is the dicey safety history of weight-loss drugs of the past, and the scant safety record that the two new agents have so far.
"The average doc with a patient who wants to lose weight would be advised to wait until we have a known track record on these drugs, and restrict their use now to patients with morbid obesity who face substantial health risks from their high excess weight."
(on Twitter @mitchelzoler)
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||NEWS PERSPECTIVE|
|Publication:||Internal Medicine News|
|Date:||Nov 15, 2012|
|Previous Article:||Insulin degludec beats sitagliptin as type 2 add-on therapy.|
|Next Article:||Combo therapy eyed for high-risk osteoporosis.|